The report was prepared by Cortellis and is entitled “Pharmaceutical innovation in the APAC region”.
It studied a cohort of 929 companies including multi-nationals across 14 countries/regions that have or are developing innovative pharmaceutical products.
Fourteen Australian companies featured in the top-100 and Pharmaxis was the second-highest ranked of the14.
Translating R&D into results
Pharmaxis’ CEO Gary Phillips said: “I’m delighted but not surprised that Pharmaxis has been recognised in this report, the first of its kind.
“We have clearly met key indicators such as being able to demonstrate a strong pipeline and translate our R&D into actual drug candidates.
“Early stage partnering was also a measure studied for the report and Pharmaxis has made this a key business objective.”
Track record of delivering value
The company’s ability to create value for shareholders through R&D is best exemplified by its 2015 deal with Boehringer.
Pharmaxis sold its anti‐inflammatory drug candidate to Boehringer in a deal structured to deliver potential value in excess of $A750 million.
The Pharmaxis drug discovery team has moved four drugs into the clinic over the last five years.
The company’s pipeline is focused on anti‐fibrotic agents to treat a variety of diseases through inhibiting the LOX and LOXL2 enzymes.
The LOXL2 inhibition program is currently in a commercial partnering process.